A message from Interactive Offers
This NYSE company’s technology could be as revolutionary for viruses as antibiotics have been for bacteria!
The biotech space is often looked at closely to see which innovative companies could change the world with their offerings. One small cap firm may soon redefine how we fight viruses with game changing broad-spectrum antiviral nanomedicines. These drugs work safely and effectively even against variants. The company’s lead drug alone addresses a $1.8 to $8 billion market! This lead drug candidate is a novel broad-spectrum antiviral that is being studied for the treatment of RSV, COVID-19, Long COVID, Influenza, Bird Flu H5N1, and other respiratory viral infections.
The treatment was substantially superior to remdesivir in coronavirus infections and was found to be substantially superior to three approved anti-influenza drugs, namely, oseltamivir (Tamiflu®, Roche), peramivir (Rapivab®, Biocryst), and baloxavir (Xofluza®, Shionogi/Roche)!
The drug, developed in response to the COVID-19 pandemic, demonstrated exceptional safety in clinical trials, even at the highest dose levels, with NO adverse events reported. The unique mechanism of action involves mimicking a cell membrane, encapsulating and blocking the virus. Beyond COVID-19, the drug also displayed promising results against respiratory syncytial virus (RSV), offering a potential solution for infants and seniors where existing treatments like ribavirin may be contraindicated due to side effects.
There is no drug for the general treatment of RSV infection at present, enabling this tiny biotech firm’s NV-387 offering to be a candidate for this $1.8 Billion to $8 Billion annual market size as estimated by GrowthPlus Reports! The company plans to advance the drug into a Phase II clinical trial for treatment of RSV infection in adults as part of the regulatory process required for registration of the drug for the treatment of pediatric RSV infection.
See how the company’s potentially revolutionary antiviral drug could fight deadly viruses like RSV while creating shareholder value.
This message is a PAID ADVERTISEMENT for NanoViricides, Inc. (NYSE American: NNVC) from Interactive Offers. StockEarnings, Inc. has received a fixed fee of $6,000 for multiple Dedicated Email Sends, Newsletter Sponsorship, and Banner Display Ads between November 15, 2024 and November 21, 2024. Other than the compensation received for this advertisement sent to subscribers, StockEarnings and its principals are not affiliated with either NanoViricides, Inc. (NYSE American: NNVC) or Interactive Offers. StockEarnings and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither StockEarnings nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from StockEarnings to buy or sell any security. StockEarnings has not evaluated the accuracy of any claims made in this advertisement. StockEarnings recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding NanoViricides, Inc. (NYSE American: NNVC) on Smallcaps Daily website for additional information about the relationship between Interactive Offers and NanoViricides, Inc. (NYSE American: NNVC).
Your privacy is very important to us, if you wish to be excluded from future notices, do not reply to this message. Instead, please click Unsubscribe.
StockEarnings, Inc
33 SE 4th St, Suite 100, Boca Raton, FL 33432 USA
W: 877.6.STOCKS
StockEarnings.com
|
